Pharmaceuticals
ADIA, GIC lead $300m round for China's Taibang Biologic
Taibang Biologic Group, a specialist in blood plasma-based pharmaceuticals formerly known as China Biologic Products, has raised a USD 300m round led by Abu Dhabi Investment Authority (ADIA) and GIC.
Portfolio: CBC Group and Ensem Therapeutics
CBC Group plans to allocate USD 300m from its latest flagship fund to a biotech incubation platform. Artificial intelligence-enabled drug discovery player Ensem Therapeutics is an example of what it wants to achieve.
China biotech player Sironax raises $200m Series B
Gaorong Capital and Yunfeng Capital have led a USD 200m Series B round for China’s Sironax, a drug developer targeting age-related degenerative diseases.
Qiming, Quan lead $120m Series B for China's OriCell
Qiming Venture Partners and Quan Capital have led a USD 120m Series B round for OriCell Therapeutics, a China-based drug developer that is working on CAR-T cell therapies that target cancer.
China's Ribo Life Science raises $40m as part of Series E
Chinese drug developer Suzhou Ribo Life Science has raised USD 40m in the first tranche of a Series E from existing investors Panlin Capital and Trinity Innovation Fund. Several undisclosed new investors also took part.
Fund focus: Qiming picks its moment
China’s Qiming Venture Partners more than doubled its fund size from the previous vintage, having launched the vehicle prior to the recent chaos and leveraged LP demand for the familiar
Australian start-up wins backing for spider venom drug
Infensa Bioscience, a newly established Brisbane-based drug developer, has raised AUD 23m (USD 15.6m) in funding to support the licensing of a nascent treatment that uses spider venom to mitigate heart attacks and strokes.
Legend leads $150m Series E for China CRO ClinChoice
US and China-based clinical contract research organization (CRO) company ClinChoice has raised a USD 150m Series E round led by Legend Capital.
China biotech: End of the boom
PE investment in China biotech has collapsed amid failed IPO processes and disputed valuations. Pockets of activity remain, though questions around commercialisation have yet to be answered
China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
5Y leads $74m round for China AI drug developer
Beijing-based HeliXon, an artificial intelligence-enabled developer of protein-based drugs, has raised CNY 500m (USD 75m) in Series A funding led by 5Y Capital. Other investors include Gaorong Capital and Neumann Capital.
China life sciences research business gets $300m Series C
MegaRobo Technologies, a China-based provider of artificial intelligence (AI) and robotics-enabled research services to the life sciences industry, has raised USD 300m in Series C funding.
Deal focus: Singapore biotech start-up generates US buzz
Singapore’s Tessa Therapeutics has developed a cancer drug that appears to be twice as effective as other treatments in its class. It has raised USD 126m with eyes on a near-term US IPO
Singapore cancer treatment start-up gets $126m Series A
Singapore’s Tessa Therapeutics, a biotech developer with a Hodgkin's lymphoma treatment in phase-two trials, has raised a USD 126m Series A round led by US healthcare specialist Polaris Partners.
Med-Fine leads Series A for China's Degron Therapeutics
US and China-based biotech player Degron Therapeutics has closed a USD 22m Series A round led by Med-Fine Capital.
Fengshi leads $45m Series D for China cancer diagnosis player
Singlera Genomics, a Shanghai-based cancer diagnostics specialist, has raised an extended Series B round of CNY 300m (USD 45m) led by Fengshi Investment Management.
China's Insilico Medicine gets $60m Series D
Insilico Medicine, a China-based artificial intelligence (AI)-driven drug discovery company, has raised a USD 60 million Series D round.
Japan's Luca Science secures $30m Series B
Luca Science, a Japanese biotech start-up focused on dysfunctional and damaged tissues and organs, has raised a USD 30.3m Series B round led by life sciences specialists 4BIO Capital and DCI Partners.
Sequoia leads Series A extension for China's ProfoundBio
Sequoia Capital China has led a USD 70m extended Series A round for ProfoundBio, a Chinese drug developer with two cancer treatments entering phase-one clinical trials.
Japan biotech start-up raises $31m Series C
Japanese cancer drug developer Chordia Therapeutics has raised JPY 4bn (USD 31.3m) in Series C funding led by Growth Capital of Japan (GCJ) and UTokyo Innovation Platform.
India's Multiples invests $88m in BDR Pharma
Multiples Private Equity has led a consortium in the acquisition of a 9.3% stake in India’s BDR Pharmaceuticals for INR 6.8bn (USD 88.5m).
Japan Industrial Solutions supports troubled local drug maker
Japan Industrial Solutions (JIS) has agreed to invest up to JPY 20bn (USD 155m) in Japan-based generic drug manufacturer Nichi-Iko Pharmaceutical with a view to saving the troubled company.
PAG backs acquisition of India's Optimus Drugs
PAG has supported the acquisition of Optimus Drugs for an undisclosed sum alongside CX Partners and Samara Capital as part of a joint Indian pharmaceuticals platform play.
China biotech player Reistone raises $100m
Reistone, a novel drug developer incubated by Jiangsu Hengrui Pharmaceuticals, has raised a Series A of nearly USD 100m led by Huagai Capital.